Insider Selling: BeOne Medicines (NASDAQ:ONC) Director Sells 212 Shares of Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Director Margaret Dugan sold 212 shares of the firm’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $309.60, for a total transaction of $65,635.20. The transaction was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

BeOne Medicines Stock Down 0.8%

ONC stock traded down $2.43 during trading on Wednesday, reaching $300.01. The stock had a trading volume of 159,041 shares, compared to its average volume of 252,436. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20. The company has a market capitalization of $32.92 billion, a price-to-earnings ratio of 67.12 and a beta of 0.50. BeOne Medicines Ltd. – Sponsored ADR has a one year low of $235.57 and a one year high of $385.22. The company’s 50 day moving average is $301.85 and its two-hundred day moving average is $321.12.

BeOne Medicines (NASDAQ:ONC) last posted its earnings results on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. The firm had revenue of $1.51 billion for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. Equities research analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post 5.65 EPS for the current year.

Wall Street Analyst Weigh In

ONC has been the subject of several research analyst reports. Barclays raised their target price on BeOne Medicines from $405.00 to $409.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Jefferies Financial Group lowered shares of BeOne Medicines from a “buy” rating to a “hold” rating and reduced their price target for the company from $420.00 to $290.00 in a research report on Monday, March 16th. Leerink Partners lifted their price objective on shares of BeOne Medicines from $364.00 to $367.00 and gave the stock an “outperform” rating in a research report on Friday, May 15th. Wolfe Research initiated coverage on shares of BeOne Medicines in a research note on Friday, March 27th. They issued an “outperform” rating and a $340.00 target price on the stock. Finally, Royal Bank Of Canada raised their price target on shares of BeOne Medicines from $423.00 to $425.00 and gave the stock an “outperform” rating in a research note on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $389.15.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Capital International Investors raised its stake in BeOne Medicines by 1.3% in the 4th quarter. Capital International Investors now owns 5,113,866 shares of the company’s stock valued at $1,553,909,000 after acquiring an additional 67,808 shares during the period. Siren L.L.C. boosted its position in BeOne Medicines by 1.4% during the fourth quarter. Siren L.L.C. now owns 500,000 shares of the company’s stock worth $151,905,000 after purchasing an additional 7,010 shares during the period. Morgan Stanley increased its stake in shares of BeOne Medicines by 23.9% in the fourth quarter. Morgan Stanley now owns 437,661 shares of the company’s stock worth $132,966,000 after purchasing an additional 84,367 shares in the last quarter. Bank of America Corp DE raised its position in shares of BeOne Medicines by 7.0% in the first quarter. Bank of America Corp DE now owns 405,273 shares of the company’s stock valued at $120,354,000 after purchasing an additional 26,441 shares during the period. Finally, Candriam S.C.A. raised its position in shares of BeOne Medicines by 31.7% in the first quarter. Candriam S.C.A. now owns 259,731 shares of the company’s stock valued at $77,132,000 after purchasing an additional 62,470 shares during the period. Institutional investors own 48.55% of the company’s stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.